Adam Bartlett

Dr. Adam Bartlett

1. Kirby Institute, University of New South Wales, Sydney 2052, Australia
+1

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2017 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
Adam BartlettAdam Bartlett
Adam Bartlett
BMBrendan McMullan
Brendan McMullan
WRWilliam D. Rawlinson
William D. Rawlinson
PPPamela Palasanthiran
Pamela Palasanthiran

1 December 2020 in Pathology
Verified
Journal Article
Closed access
PWPhoebe C.M. Williams
Phoebe C.M. Williams
AHAnnaleise R. Howard-Jones
Annaleise R. Howard-Jones
PHPeter Hsu
Peter Hsu
PPPamela Palasanthiran
Pamela Palasanthiran
PGPaul E. Gray
Paul E. Gray
Adam BartlettAdam Bartlett
Adam Bartlett

18 November 2021 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
PWPhoebe Cm Williams
Phoebe Cm Williams
Adam BartlettAdam Bartlett
Adam Bartlett
AHAnnaleise R. Howard-Jones
Annaleise R. Howard-Jones
BMBrendan McMullan
Brendan McMullan
AKAmeneh Khatami
Ameneh Khatami
Ben J. MaraisBen J. Marais
Ben J. Marais

16 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SWStacie S. Wang
Stacie S. Wang
RKRishi S Kotecha
Rishi S Kotecha
ABAnne Bernard
Anne Bernard
CBChristopher C. Blyth
Christopher C. Blyth
BMBrendan J. McMullan
Brendan J. McMullan
GHGabrielle M. Haeusler
Gabrielle M. Haeusler

4 December 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Adam BartlettAdam Bartlett
Adam Bartlett
MCMegan P. Cann
Megan P. Cann
DYDaniel K. Yeoh
Daniel K. Yeoh
ABAnne Bernard
Anne Bernard
ARAnne L. Ryan
Anne L. Ryan
JCJulia E. Clark
Julia E. Clark

19 January 2022 in Cell Reports
Verified
Journal Article
Open access
HBHarikrishnan Balachandran
Harikrishnan Balachandran
CPChansavath Phetsouphanh
Chansavath Phetsouphanh
DADavid Agapiou
David Agapiou
AAAnurag Adhikari
Anurag Adhikari
CRChaturaka Rodrigo
Chaturaka Rodrigo
RBRowena Bull
Rowena Bull
Understanding the long-term maintenance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity is critical for predicting protection against reinfection. In an age- and gender-matched cohort of 24 participants, the association of disease severity and early immune responses on the maintenance of humoral immunity 12 months post-infection is examined. All severely affected participants maintain a stable subset of SARS-CoV-2 receptor-binding domain (RBD)-specific memory B cells (MBCs) and good neutralizing antibody breadth against the majority of the variants of concern, including the Delta variant. Modeling these immune responses against vaccine efficacy data indicate a 45%–76% protection against symptomatic infection (variant dependent). Overall, these findings indicate durable humoral responses in most participants after infection, reasonable protection against reinfection, and implicate baseline antigen-specific CD4+ T cell responses as a predictor of maintenance of antibody neutralization breadth and RBD-specific MBC levels at 12 months post-infection.